 | • レポートコード：MRC2Q12-03828 • 出版社/出版日：QYResearch / 2022年12月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：化学&材料 |
| Single User | ￥710,500 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,421,000 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、チゲサイクリンAPIのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 チゲサイクリンAPIのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 チゲサイクリンAPIの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 チゲサイクリンAPIのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までのチゲサイクリンAPIの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のチゲサイクリンAPIの売上および2028年までの予測に焦点を当てています。 チゲサイクリンAPIのグローバル主要企業には、Sun Pharma、Teva、Transo-Pharm USA LLC、Rochem International Inc、NEWEDGE Overseas、Mac-Chem Products (India) Pvt.Ltd、Chongqing Fuan Pharmaceutical、WUHAN ZY PHARMACEUTICAL CO LTD、Melody Healthcare Pvt Ltd、Zhejiang Hisun Pharmaceutical、Olon S.p.A、HAORUI ENTERPRISES LIMITED、HANWAYS PHARMCHEM CO., LTD.、Sumar Biotechなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 チゲサイクリンAPI市場は、タイプとアプリケーションによって区分されます。世界のチゲサイクリンAPI市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 98%以上、99%以上 【アプリケーション別セグメント】 注射、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - チゲサイクリンAPI製品概要 - タイプ別市場（98%以上、99%以上） - アプリケーション別市場（注射、その他） - 調査の目的 ・エグゼクティブサマリー - 世界のチゲサイクリンAPI販売量予測2017-2028 - 世界のチゲサイクリンAPI売上予測2017-2028 - チゲサイクリンAPIの地域別販売量 - チゲサイクリンAPIの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別チゲサイクリンAPI販売量 - 主要メーカー別チゲサイクリンAPI売上 - 主要メーカー別チゲサイクリンAPI価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（98%以上、99%以上） - チゲサイクリンAPIのタイプ別販売量 - チゲサイクリンAPIのタイプ別売上 - チゲサイクリンAPIのタイプ別価格 ・アプリケーション別市場規模（注射、その他） - チゲサイクリンAPIのアプリケーション別販売量 - チゲサイクリンAPIのアプリケーション別売上 - チゲサイクリンAPIのアプリケーション別価格 ・北米市場 - 北米のチゲサイクリンAPI市場規模（タイプ別、アプリケーション別） - 主要国別のチゲサイクリンAPI市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのチゲサイクリンAPI市場規模（タイプ別、アプリケーション別） - 主要国別のチゲサイクリンAPI市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のチゲサイクリンAPI市場規模（タイプ別、アプリケーション別） - 主要国別のチゲサイクリンAPI市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のチゲサイクリンAPI市場規模（タイプ別、アプリケーション別） - 主要国別のチゲサイクリンAPI市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのチゲサイクリンAPI市場規模（タイプ別、アプリケーション別） - 主要国別のチゲサイクリンAPI市場規模（トルコ、サウジアラビア） ・企業情報 Sun Pharma、Teva、Transo-Pharm USA LLC、Rochem International Inc、NEWEDGE Overseas、Mac-Chem Products (India) Pvt.Ltd、Chongqing Fuan Pharmaceutical、WUHAN ZY PHARMACEUTICAL CO LTD、Melody Healthcare Pvt Ltd、Zhejiang Hisun Pharmaceutical、Olon S.p.A、HAORUI ENTERPRISES LIMITED、HANWAYS PHARMCHEM CO., LTD.、Sumar Biotech ・産業チェーン及び販売チャネル分析 - チゲサイクリンAPIの産業チェーン分析 - チゲサイクリンAPIの原材料 - チゲサイクリンAPIの生産プロセス - チゲサイクリンAPIの販売及びマーケティング - チゲサイクリンAPIの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - チゲサイクリンAPIの産業動向 - チゲサイクリンAPIのマーケットドライバー - チゲサイクリンAPIの課題 - チゲサイクリンAPIの阻害要因 ・主な調査結果 |
Tigecycline (CAS：220620-09-7),is an tetracycline antibiotic medication for a number of bacterial infections.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Tigecycline API estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Tigecycline API is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Tigecycline API is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Tigecycline API is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Tigecycline API include Sun Pharma, Teva, Transo-Pharm USA LLC, Rochem International Inc, NEWEDGE Overseas, Mac-Chem Products (India) Pvt.Ltd, Chongqing Fuan Pharmaceutical, WUHAN ZY PHARMACEUTICAL CO LTD and Melody Healthcare Pvt Ltd, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
In terms of production side, this report researches the Tigecycline API production, growth rate, market share by manufacturers and by region (region level and country level), from 2017 to 2022, and forecast to 2028.
In terms of sales side, this report focuses on the sales of Tigecycline API by region (region level and country level), by company, by Purity and by Application. from 2017 to 2022 and forecast to 2028.
Report Scope
This latest report researches the industry structure, capacity, production, sales (consumption), revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Tigecycline API manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Tigecycline API market. Further, it explains the major drivers and regional dynamics of the global Tigecycline API market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Sun Pharma
Teva
Transo-Pharm USA LLC
Rochem International Inc
NEWEDGE Overseas
Mac-Chem Products (India) Pvt.Ltd
Chongqing Fuan Pharmaceutical
WUHAN ZY PHARMACEUTICAL CO LTD
Melody Healthcare Pvt Ltd
Zhejiang Hisun Pharmaceutical
Olon S.p.A
HAORUI ENTERPRISES LIMITED
HANWAYS PHARMCHEM CO., LTD.
Sumar Biotech
Market Segments
This report has explored the key segments: by Purity and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on production, price, and value for the period 2017-2028.
Tigecycline API Segment by Purity
Above 98 %
Above 99 %
Tigecycline API Segment by Application
Injection
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. This report analyzes the Tigecycline API production by region/country, and the sales (consumption) by region/country. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Tigecycline API market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Tigecycline API, capacity, output, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Tigecycline API, also provides the consumption of main regions and countries. Highlights of the upcoming market potential for Tigecycline API, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Tigecycline API sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Tigecycline API market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Tigecycline API sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Sun Pharma, Teva, Transo-Pharm USA LLC, Rochem International Inc, NEWEDGE Overseas, Mac-Chem Products (India) Pvt.Ltd, Chongqing Fuan Pharmaceutical, WUHAN ZY PHARMACEUTICAL CO LTD and Melody Healthcare Pvt Ltd, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Tigecycline API capacity, production/output of global and key producers (regions/countries). It provides a quantitative analysis of the capacity, production, and development potential of each producer in the next six years.
Chapter 3: Sales (consumption), revenue of Tigecycline API in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Tigecycline API manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by purity, by application and by country, sales and revenue for each segment.
Chapter 8: Europe by purity, by application and by country, sales and revenue for each segment.
Chapter 9: Asia Pacific by purity, by application and by country, sales and revenue for each segment.
Chapter 10: Latin America by purity, by application and by country, sales and revenue for each segment.
Chapter 11: Middle East and Africa by purity, by application and by country, sales and revenue for each segment.
Chapter 12: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Tigecycline API sales, revenue, price, gross margin, and recent development, etc.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 15: The main points and conclusions of the report.
1 Study Coverage
1.1 Tigecycline API Product Introduction
1.2 Market by Purity
1.2.1 Global Tigecycline API Market Size by Purity, 2017 VS 2021 VS 2028
1.2.2 Above 98 %
1.2.3 Above 99 %
1.3 Market by Application
1.3.1 Global Tigecycline API Market Size by Application, 2017 VS 2021 VS 2028
1.3.2 Injection
1.3.3 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Tigecycline API Production
2.1 Global Tigecycline API Production Capacity (2017-2028)
2.2 Global Tigecycline API Production by Region: 2017 VS 2021 VS 2028
2.3 Global Tigecycline API Production by Region
2.3.1 Global Tigecycline API Historic Production by Region (2017-2022)
2.3.2 Global Tigecycline API Forecasted Production by Region (2023-2028)
2.4 North America
2.5 Europe
2.6 China
2.7 India
2.8 Israel
3 Global Tigecycline API Sales in Volume & Value Estimates and Forecasts
3.1 Global Tigecycline API Sales Estimates and Forecasts 2017-2028
3.2 Global Tigecycline API Revenue Estimates and Forecasts 2017-2028
3.3 Global Tigecycline API Revenue by Region: 2017 VS 2021 VS 2028
3.4 Global Tigecycline API Sales by Region
3.4.1 Global Tigecycline API Sales by Region (2017-2022)
3.4.2 Global Sales Tigecycline API by Region (2023-2028)
3.5 Global Tigecycline API Revenue by Region
3.5.1 Global Tigecycline API Revenue by Region (2017-2022)
3.5.2 Global Tigecycline API Revenue by Region (2023-2028)
3.6 North America
3.7 Europe
3.8 Asia-Pacific
3.9 Latin America
3.10 Middle East & Africa
4 Competition by Manufactures
4.1 Global Tigecycline API Production Capacity by Manufacturers
4.2 Global Tigecycline API Sales by Manufacturers
4.2.1 Global Tigecycline API Sales by Manufacturers (2017-2022)
4.2.2 Global Tigecycline API Sales Market Share by Manufacturers (2017-2022)
4.2.3 Global Top 10 and Top 5 Largest Manufacturers of Tigecycline API in 2021
4.3 Global Tigecycline API Revenue by Manufacturers
4.3.1 Global Tigecycline API Revenue by Manufacturers (2017-2022)
4.3.2 Global Tigecycline API Revenue Market Share by Manufacturers (2017-2022)
4.3.3 Global Top 10 and Top 5 Companies by Tigecycline API Revenue in 2021
4.4 Global Tigecycline API Sales Price by Manufacturers
4.5 Analysis of Competitive Landscape
4.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
4.5.2 Global Tigecycline API Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.5.3 Global Tigecycline API Manufacturers Geographical Distribution
4.6 Mergers & Acquisitions, Expansion Plans
5 Market Size by Purity
5.1 Global Tigecycline API Sales by Purity
5.1.1 Global Tigecycline API Historical Sales by Purity (2017-2022)
5.1.2 Global Tigecycline API Forecasted Sales by Purity (2023-2028)
5.1.3 Global Tigecycline API Sales Market Share by Purity (2017-2028)
5.2 Global Tigecycline API Revenue by Purity
5.2.1 Global Tigecycline API Historical Revenue by Purity (2017-2022)
5.2.2 Global Tigecycline API Forecasted Revenue by Purity (2023-2028)
5.2.3 Global Tigecycline API Revenue Market Share by Purity (2017-2028)
5.3 Global Tigecycline API Price by Purity
5.3.1 Global Tigecycline API Price by Purity (2017-2022)
5.3.2 Global Tigecycline API Price Forecast by Purity (2023-2028)
6 Market Size by Application
6.1 Global Tigecycline API Sales by Application
6.1.1 Global Tigecycline API Historical Sales by Application (2017-2022)
6.1.2 Global Tigecycline API Forecasted Sales by Application (2023-2028)
6.1.3 Global Tigecycline API Sales Market Share by Application (2017-2028)
6.2 Global Tigecycline API Revenue by Application
6.2.1 Global Tigecycline API Historical Revenue by Application (2017-2022)
6.2.2 Global Tigecycline API Forecasted Revenue by Application (2023-2028)
6.2.3 Global Tigecycline API Revenue Market Share by Application (2017-2028)
6.3 Global Tigecycline API Price by Application
6.3.1 Global Tigecycline API Price by Application (2017-2022)
6.3.2 Global Tigecycline API Price Forecast by Application (2023-2028)
7 North America
7.1 North America Tigecycline API Market Size by Purity
7.1.1 North America Tigecycline API Sales by Purity (2017-2028)
7.1.2 North America Tigecycline API Revenue by Purity (2017-2028)
7.2 North America Tigecycline API Market Size by Application
7.2.1 North America Tigecycline API Sales by Application (2017-2028)
7.2.2 North America Tigecycline API Revenue by Application (2017-2028)
7.3 North America Tigecycline API Sales by Country
7.3.1 North America Tigecycline API Sales by Country (2017-2028)
7.3.2 North America Tigecycline API Revenue by Country (2017-2028)
7.3.3 United States
7.3.4 Canada
8 Europe
8.1 Europe Tigecycline API Market Size by Purity
8.1.1 Europe Tigecycline API Sales by Purity (2017-2028)
8.1.2 Europe Tigecycline API Revenue by Purity (2017-2028)
8.2 Europe Tigecycline API Market Size by Application
8.2.1 Europe Tigecycline API Sales by Application (2017-2028)
8.2.2 Europe Tigecycline API Revenue by Application (2017-2028)
8.3 Europe Tigecycline API Sales by Country
8.3.1 Europe Tigecycline API Sales by Country (2017-2028)
8.3.2 Europe Tigecycline API Revenue by Country (2017-2028)
8.3.3 Germany
8.3.4 France
8.3.5 U.K.
8.3.6 Italy
8.3.7 Russia
9 Asia Pacific
9.1 Asia Pacific Tigecycline API Market Size by Purity
9.1.1 Asia Pacific Tigecycline API Sales by Purity (2017-2028)
9.1.2 Asia Pacific Tigecycline API Revenue by Purity (2017-2028)
9.2 Asia Pacific Tigecycline API Market Size by Application
9.2.1 Asia Pacific Tigecycline API Sales by Application (2017-2028)
9.2.2 Asia Pacific Tigecycline API Revenue by Application (2017-2028)
9.3 Asia Pacific Tigecycline API Sales by Region
9.3.1 Asia Pacific Tigecycline API Sales by Region (2017-2028)
9.3.2 Asia Pacific Tigecycline API Revenue by Region (2017-2028)
9.3.3 China
9.3.4 Japan
9.3.5 South Korea
9.3.6 India
9.3.7 Australia
9.3.8 China Taiwan
9.3.9 Indonesia
9.3.10 Thailand
9.3.11 Malaysia
10 Latin America
10.1 Latin America Tigecycline API Market Size by Purity
10.1.1 Latin America Tigecycline API Sales by Purity (2017-2028)
10.1.2 Latin America Tigecycline API Revenue by Purity (2017-2028)
10.2 Latin America Tigecycline API Market Size by Application
10.2.1 Latin America Tigecycline API Sales by Application (2017-2028)
10.2.2 Latin America Tigecycline API Revenue by Application (2017-2028)
10.3 Latin America Tigecycline API Sales by Country
10.3.1 Latin America Tigecycline API Sales by Country (2017-2028)
10.3.2 Latin America Tigecycline API Revenue by Country (2017-2028)
10.3.3 Mexico
10.3.4 Brazil
10.3.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Tigecycline API Market Size by Purity
11.1.1 Middle East and Africa Tigecycline API Sales by Purity (2017-2028)
11.1.2 Middle East and Africa Tigecycline API Revenue by Purity (2017-2028)
11.2 Middle East and Africa Tigecycline API Market Size by Application
11.2.1 Middle East and Africa Tigecycline API Sales by Application (2017-2028)
11.2.2 Middle East and Africa Tigecycline API Revenue by Application (2017-2028)
11.3 Middle East and Africa Tigecycline API Sales by Country
11.3.1 Middle East and Africa Tigecycline API Sales by Country (2017-2028)
11.3.2 Middle East and Africa Tigecycline API Revenue by Country (2017-2028)
11.3.3 Turkey
11.3.4 Saudi Arabia
11.3.5 UAE
12 Corporate Profiles
12.1 Sun Pharma
12.1.1 Sun Pharma Corporation Information
12.1.2 Sun Pharma Overview
12.1.3 Sun Pharma Tigecycline API Sales, Price, Revenue and Gross Margin (2017-2022)
12.1.4 Sun Pharma Tigecycline API Product Model Numbers, Pictures, Descriptions and Specifications
12.1.5 Sun Pharma Recent Developments
12.2 Teva
12.2.1 Teva Corporation Information
12.2.2 Teva Overview
12.2.3 Teva Tigecycline API Sales, Price, Revenue and Gross Margin (2017-2022)
12.2.4 Teva Tigecycline API Product Model Numbers, Pictures, Descriptions and Specifications
12.2.5 Teva Recent Developments
12.3 Transo-Pharm USA LLC
12.3.1 Transo-Pharm USA LLC Corporation Information
12.3.2 Transo-Pharm USA LLC Overview
12.3.3 Transo-Pharm USA LLC Tigecycline API Sales, Price, Revenue and Gross Margin (2017-2022)
12.3.4 Transo-Pharm USA LLC Tigecycline API Product Model Numbers, Pictures, Descriptions and Specifications
12.3.5 Transo-Pharm USA LLC Recent Developments
12.4 Rochem International Inc
12.4.1 Rochem International Inc Corporation Information
12.4.2 Rochem International Inc Overview
12.4.3 Rochem International Inc Tigecycline API Sales, Price, Revenue and Gross Margin (2017-2022)
12.4.4 Rochem International Inc Tigecycline API Product Model Numbers, Pictures, Descriptions and Specifications
12.4.5 Rochem International Inc Recent Developments
12.5 NEWEDGE Overseas
12.5.1 NEWEDGE Overseas Corporation Information
12.5.2 NEWEDGE Overseas Overview
12.5.3 NEWEDGE Overseas Tigecycline API Sales, Price, Revenue and Gross Margin (2017-2022)
12.5.4 NEWEDGE Overseas Tigecycline API Product Model Numbers, Pictures, Descriptions and Specifications
12.5.5 NEWEDGE Overseas Recent Developments
12.6 Mac-Chem Products (India) Pvt.Ltd
12.6.1 Mac-Chem Products (India) Pvt.Ltd Corporation Information
12.6.2 Mac-Chem Products (India) Pvt.Ltd Overview
12.6.3 Mac-Chem Products (India) Pvt.Ltd Tigecycline API Sales, Price, Revenue and Gross Margin (2017-2022)
12.6.4 Mac-Chem Products (India) Pvt.Ltd Tigecycline API Product Model Numbers, Pictures, Descriptions and Specifications
12.6.5 Mac-Chem Products (India) Pvt.Ltd Recent Developments
12.7 Chongqing Fuan Pharmaceutical
12.7.1 Chongqing Fuan Pharmaceutical Corporation Information
12.7.2 Chongqing Fuan Pharmaceutical Overview
12.7.3 Chongqing Fuan Pharmaceutical Tigecycline API Sales, Price, Revenue and Gross Margin (2017-2022)
12.7.4 Chongqing Fuan Pharmaceutical Tigecycline API Product Model Numbers, Pictures, Descriptions and Specifications
12.7.5 Chongqing Fuan Pharmaceutical Recent Developments
12.8 WUHAN ZY PHARMACEUTICAL CO LTD
12.8.1 WUHAN ZY PHARMACEUTICAL CO LTD Corporation Information
12.8.2 WUHAN ZY PHARMACEUTICAL CO LTD Overview
12.8.3 WUHAN ZY PHARMACEUTICAL CO LTD Tigecycline API Sales, Price, Revenue and Gross Margin (2017-2022)
12.8.4 WUHAN ZY PHARMACEUTICAL CO LTD Tigecycline API Product Model Numbers, Pictures, Descriptions and Specifications
12.8.5 WUHAN ZY PHARMACEUTICAL CO LTD Recent Developments
12.9 Melody Healthcare Pvt Ltd
12.9.1 Melody Healthcare Pvt Ltd Corporation Information
12.9.2 Melody Healthcare Pvt Ltd Overview
12.9.3 Melody Healthcare Pvt Ltd Tigecycline API Sales, Price, Revenue and Gross Margin (2017-2022)
12.9.4 Melody Healthcare Pvt Ltd Tigecycline API Product Model Numbers, Pictures, Descriptions and Specifications
12.9.5 Melody Healthcare Pvt Ltd Recent Developments
12.10 Zhejiang Hisun Pharmaceutical
12.10.1 Zhejiang Hisun Pharmaceutical Corporation Information
12.10.2 Zhejiang Hisun Pharmaceutical Overview
12.10.3 Zhejiang Hisun Pharmaceutical Tigecycline API Sales, Price, Revenue and Gross Margin (2017-2022)
12.10.4 Zhejiang Hisun Pharmaceutical Tigecycline API Product Model Numbers, Pictures, Descriptions and Specifications
12.10.5 Zhejiang Hisun Pharmaceutical Recent Developments
12.11 Olon S.p.A
12.11.1 Olon S.p.A Corporation Information
12.11.2 Olon S.p.A Overview
12.11.3 Olon S.p.A Tigecycline API Sales, Price, Revenue and Gross Margin (2017-2022)
12.11.4 Olon S.p.A Tigecycline API Product Model Numbers, Pictures, Descriptions and Specifications
12.11.5 Olon S.p.A Recent Developments
12.12 HAORUI ENTERPRISES LIMITED
12.12.1 HAORUI ENTERPRISES LIMITED Corporation Information
12.12.2 HAORUI ENTERPRISES LIMITED Overview
12.12.3 HAORUI ENTERPRISES LIMITED Tigecycline API Sales, Price, Revenue and Gross Margin (2017-2022)
12.12.4 HAORUI ENTERPRISES LIMITED Tigecycline API Product Model Numbers, Pictures, Descriptions and Specifications
12.12.5 HAORUI ENTERPRISES LIMITED Recent Developments
12.13 HANWAYS PHARMCHEM CO., LTD.
12.13.1 HANWAYS PHARMCHEM CO., LTD. Corporation Information
12.13.2 HANWAYS PHARMCHEM CO., LTD. Overview
12.13.3 HANWAYS PHARMCHEM CO., LTD. Tigecycline API Sales, Price, Revenue and Gross Margin (2017-2022)
12.13.4 HANWAYS PHARMCHEM CO., LTD. Tigecycline API Product Model Numbers, Pictures, Descriptions and Specifications
12.13.5 HANWAYS PHARMCHEM CO., LTD. Recent Developments
12.14 Sumar Biotech
12.14.1 Sumar Biotech Corporation Information
12.14.2 Sumar Biotech Overview
12.14.3 Sumar Biotech Tigecycline API Sales, Price, Revenue and Gross Margin (2017-2022)
12.14.4 Sumar Biotech Tigecycline API Product Model Numbers, Pictures, Descriptions and Specifications
12.14.5 Sumar Biotech Recent Developments
13 Industry Chain and Sales Channels Analysis
13.1 Tigecycline API Industry Chain Analysis
13.2 Tigecycline API Key Raw Materials
13.2.1 Key Raw Materials
13.2.2 Raw Materials Key Suppliers
13.3 Tigecycline API Production Mode & Process
13.4 Tigecycline API Sales and Marketing
13.4.1 Tigecycline API Sales Channels
13.4.2 Tigecycline API Distributors
13.5 Tigecycline API Customers
14 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
14.1 Tigecycline API Industry Trends
14.2 Tigecycline API Market Drivers
14.3 Tigecycline API Market Challenges
14.4 Tigecycline API Market Restraints
15 Key Finding in The Global Tigecycline API Study
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
| 【チゲサイクリンAPIについて】 チゲサイクリンは、抗生物質の一種で、特に広範囲のグラム陽性菌およびグラム陰性菌に対して効果を示すことから、臨床での利用が進められています。今回はチゲサイクリンの定義、特徴、種類、用途、関連技術などについて考察します。 チゲサイクリンは、グリシルサイクリンと呼ばれる抗菌薬の一つで、2005年にアメリカで承認されました。この薬剤はテトラサイクリンに関連する化学構造を持ちながらも、特定の構造変化を持つことで、従来のテトラサイクリン系抗菌薬に対する耐性を持つ菌に対しても有効です。これは、特に医療機関内での感染症に対して重要な意味を持ちます。 チゲサイクリンの主な特徴としては、広範な抗菌スペクトルが挙げられます。具体的には、グラム陽性菌、グラム陰性菌、さらには嫌気性菌に対しても効果があります。これにより、重症感染症や多剤耐性菌感染に対して使用されることが多いです。また、体内での広がりが良く、組織に高い濃度で到達することができるため、感染部位における薬の効果が期待されます。 他の抗生物質と同様に、チゲサイクリンの使用にはいくつかの制約があります。成人においては肝機能にかかわる副作用が報告されており、特に肝障害のある患者への使用に際しては慎重が求められます。また、妊娠中や授乳中の使用は避けるべきとされています。さらに、チゲサイクリンは経口投与ではなく、静脈注射での投与が必要です。 用途としては、重症菌血症、複雑な皮膚および軟部組織感染、腹膜炎などが挙げられます。特に多剤耐性菌による感染症が問題視される今、チゲサイクリンはそれに対抗する手段の一つとして位置付けられています。皮膚感染症においては、特に難治性のものに対応することが多く、臨床現場での需要が高まっています。 チゲサイクリンの関連技術としては、臨床試験を通じた効果の評価や、耐性菌に対する感受性試験などが重要となります。これにより、使用されるべき患者に対して最適な治療方法が導き出すことができます。また、医療技術の進歩により、遺伝子解析を活用した耐性菌の検出方法や、薬物動態解析を行うことで、より効果的な治療戦略が模索されています。 ただし、チゲサイクリンを含む広範囲の抗生物質に共通する課題として、耐性菌の増加があります。これに対抗するためには、抗生物質の適正使用が不可欠です。具体的には、必要な場合のみ使用し、過剰な処方を避けることが求められます。また、耐性菌が発生した場合には、直ちに別の治療法に切り替える必要があるため、迅速な診断技術の向上も必要です。 最近の研究では、チゲサイクリンの使用に関する新たな知見も報告されています。例えば、多剤耐性菌による感染症の治療において、他の抗生物質との併用療法が効果的であることが示唆されており、今後の治療戦略に影響を与えると言われています。これにより、特に複雑な感染症における治療方法が多様化することが期待されています。 チゲサイクリンのアプローチは、今後の感染症治療において重要な役割を果たすと考えられます。抗菌薬の耐性問題が深刻化するなか、チゲサイクリンの利用は依然として価値が高いですが、その使用には注意が必要です。今後は、研究の進展や新たな技術の開発を通じて、チゲサイクリン及びその他の抗生物質の適正な使用法が確立されることが望まれます。 総じて、チゲサイクリンは、特に重症感染症や多剤耐性菌に対する強力な武器として、今後も医療現場での活用が期待されています。その特性や適切な使用法を理解することで、感染症治療における戦略の一端を担うことができるでしょう。医療従事者にとっては、その効果と副作用についての知識を深め、患者への最適な治療を提供することが求められます。 |